GoodRX, Weight Watchers, LifeMD Offering Novo Nordisk's New Weight-Loss Pill

Dow Jones

01/05

By Connor Hart

GoodRX, Weight Watchers and LifeMD all said they will offer Novo Nordisk's new weight-loss pill, Wegovy, on their respective platforms.

U.S. regulators approved the new pill last month. At that time, Novo Nordisk said it planned to start selling the pill in the U.S. in early January, with a cash price of $149 a month for the starting dose.

Drug companies and analysts have said the pills will tap in to demand from people who don't want an injection or would prefer the cadence of a daily dose. Pills also offer the prospect of lower prices and better health-insurance coverage than injections, because pills cost less to make, The Wall Street Journal previously reported.

GoodRX, Weight Watchers and LifeMD all expanded their partnerships with Novo Nordisk to offer the new weight-loss pill through their respective platforms, a push to further expand access to popular GLP-1 treatments.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 05, 2026 08:42 ET (13:42 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2601788497"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601788497\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601788497?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601788497","market":"hk","top_or_hot":-1,"title":"GoodRX, Weight Watchers, LifeMD Offering Novo Nordisk's New Weight-Loss Pill","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  GoodRX, Weight Watchers and LifeMD all said they will offer <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s new weight-loss pill, Wegovy, on their respective platforms. \n</p>\n<p>\n  U.S. regulators approved the new pill last month. At that time, Novo Nordisk said it planned to start selling the pill in the U.S. in early January, with a cash price of $149 a month for the starting dose. \n</p>\n<p>\n  Drug companies and analysts have said the pills will tap in to demand from people who don't want an injection or would prefer the cadence of a daily dose. Pills also offer the prospect of lower prices and better health-insurance coverage than injections, because pills cost less to make, The Wall Street Journal previously reported. \n</p>\n<p>\n  GoodRX, Weight Watchers and LifeMD all expanded their partnerships with Novo Nordisk to offer the new weight-loss pill through their respective platforms, a push to further expand access to popular GLP-1 treatments. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 05, 2026 08:42 ET (13:42 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GoodRX, Weight Watchers, LifeMD Offering Novo Nordisk's New Weight-Loss Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoodRX, Weight Watchers, LifeMD Offering Novo Nordisk's New Weight-Loss Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-05 21:42</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  GoodRX, Weight Watchers and LifeMD all said they will offer <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s new weight-loss pill, Wegovy, on their respective platforms. \n</p>\n<p>\n  U.S. regulators approved the new pill last month. At that time, Novo Nordisk said it planned to start selling the pill in the U.S. in early January, with a cash price of $149 a month for the starting dose. \n</p>\n<p>\n  Drug companies and analysts have said the pills will tap in to demand from people who don't want an injection or would prefer the cadence of a daily dose. Pills also offer the prospect of lower prices and better health-insurance coverage than injections, because pills cost less to make, The Wall Street Journal previously reported. \n</p>\n<p>\n  GoodRX, Weight Watchers and LifeMD all expanded their partnerships with Novo Nordisk to offer the new weight-loss pill through their respective platforms, a push to further expand access to popular GLP-1 treatments. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 05, 2026 08:42 ET (13:42 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4183","symbol_name":"个人用品","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2601788497","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601788497","pubTimestamp":1767620520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"GoodRX, Weight Watchers and LifeMD all said they will offer Novo Nordisk's new weight-loss pill, Wegovy, on their respective platforms.U.S. regulators approved the new pill last month. At that time, Novo Nordisk said it planned to start selling the pill in the U.S. in early January, with a cash price of $149 a month for the starting dose.Drug companies and analysts have said the pills will tap in to demand from people who don't want an injection or would prefer the cadence of a daily dose. Pills also offer the prospect of lower prices and better health-insurance coverage than injections, because pills cost less to make, The Wall Street Journal previously reported.GoodRX, Weight Watchers and LifeMD all expanded their partnerships with Novo Nordisk to offer the new weight-loss pill through their respective platforms, a push to further expand access to popular GLP-1 treatments.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4183":"个人用品","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","LFMD":"LifeMD Inc.","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4167":"医疗保健技术","BK4192":"特殊消费者服务","BK4599":"减肥药","BK4007":"制药","GDRX":"GoodRx Holdings, Inc.","WW":"WW International, Inc.","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD"},"translate_title":"GoodRX、慧俪轻体、LifeMD提供诺和诺德的新型减肥药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WW":1.91,"LFMD":1.91,"GDRX":1.91},"content_text":"By Connor Hart \n\n\n \n\n\n  GoodRX, Weight Watchers and LifeMD all said they will offer Novo Nordisk's new weight-loss pill, Wegovy, on their respective platforms. \n\n\n  U.S. regulators approved the new pill last month. At that time, Novo Nordisk said it planned to start selling the pill in the U.S. in early January, with a cash price of $149 a month for the starting dose. \n\n\n  Drug companies and analysts have said the pills will tap in to demand from people who don't want an injection or would prefer the cadence of a daily dose. Pills also offer the prospect of lower prices and better health-insurance coverage than injections, because pills cost less to make, The Wall Street Journal previously reported. \n\n\n  GoodRX, Weight Watchers and LifeMD all expanded their partnerships with Novo Nordisk to offer the new weight-loss pill through their respective platforms, a push to further expand access to popular GLP-1 treatments. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 05, 2026 08:42 ET (13:42 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}